Strikingly, when co-loaded with the Mycobacterium tuberculosis antigen 85B peptide 25, the TLR8-agonist containing polymersomes were comparable to BCG in inducing antigen-specific immune responses in human TLR8-expressing neonatal mice in vivo.68 This is promising, since BCG reduces the risk of disseminated early life tuberculosis by safely eliciting Th1-type neonatal immune responses and requires only a single dose at or shortly after the time of birth. Here, TLR8 is linked to tuberculosis.